Depending on tumor stage, a Canadian study reported 5-year survival rates between 96.5% (stage I) to 36.6% (stage IV) for HER2+, 94.7% to 24% for HR+, and 93.3% to 7.4% for TNBC (26). The gene discussed is ERBB2; the disease is neoplasm.